From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
EGIS-12233 structure.png
Clinical data
ATC code
  • none
PubChem CID
Chemical and physical data
Molar mass480.856 g/mol g·mol−1
3D model (JSmol)

EGIS-12,233 is a drug with applications in scientific research, acting as a potent and selective antagonist for both the 5-HT6 and 5-HT7 serotonin receptor subtypes, with good selectivity over other receptors.[1] It has been shown to increase dopamine release in cochlear tissue, suggesting a role for the 5-HT6 and 5-HT7 receptors in regulation of the hearing system.[2]


  1. ^ Volk, B; Barkóczy, J; Hegedus, E; Udvari, S; Gacsályi, I; Mezei, T; Pallagi, K; Kompagne, H; et al. (2008). "(Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists". Journal of Medicinal Chemistry. 51 (8): 2522–32. doi:10.1021/jm070279v. PMID 18361484.
  2. ^ Doleviczényi, Z; Vizi, ES; Gacsályi, I; Pallagi, K; Volk, B; Hársing Jr, LG; Halmos, G; Lendvai, B; Zelles, T (2008). "5-HT6/7 receptor antagonists facilitate dopamine release in the cochlea via a GABAergic disinhibitory mechanism". Neurochemical Research. 33 (11): 2364–72. doi:10.1007/s11064-008-9796-4. PMID 18663573.